Application of alpinetin in preparation of medicine for preventing and treating osteoporosis

A technology of osteoporosis and alpinol, applied in the field of medicine, can solve the problems of venous thromboembolism, calcium ion loss, high price, etc., and achieve the effect of alleviating osteoporosis

Pending Publication Date: 2021-06-25
中山大学附属第八医院
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these drugs are prone to cause vasoconstriction, venous thromboembolism, loss of calcium ions in the body, and complications such as breast cancer, cervical cancer, and endometrial cancer, and are very expensive
However, there is no report about the use of alpinus in the treatment of osteoporosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of alpinetin in preparation of medicine for preventing and treating osteoporosis
  • Application of alpinetin in preparation of medicine for preventing and treating osteoporosis
  • Application of alpinetin in preparation of medicine for preventing and treating osteoporosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] The preparation of embodiment 1 alpinol medicinal liquid

[0030] Purchase Alpinia drug powder with CAS item number 36052-376, weigh 20mg of the powder, add 740uL sterile DMSO according to the mother solution preparation instructions to make a drug mother solution with a concentration of 100mM, wait for the mother solution to fully dissolve, and seal it with EP tubes. Quick-frozen with liquid nitrogen and stored at -20°C for later use. Using an osteogenic induction medium (the osteogenic induction medium is DMEM basal medium containing 10% fetal bovine serum, 100 IU / mL penicillin / streptomycin, 0.1 μM dexamethasone, 10 mM β-glycerol phosphate and 50 μM ascorbic acid, the mountain Gingerin mother solution was diluted to the required working concentration (5-20 μM) and then added to the cells for osteogenic induction.

Embodiment 2

[0031] Embodiment 2 Alpine ginger dose-dependently enhances MSCs (mesenchymal stem cells) osteogenic differentiation

[0032] The human-derived MSCs were isolated in strict accordance with the requirements for stem cell isolation and culture (refer to the literature for the isolation method: Peng W, Li Y, Huang L. Effects and safety of allogenic mesenchymal stem cell in travenous infusion in active ankylosing spondylitis patients who failed NSAIDs: a 20-week clinical trial .[J].Cell Transplantation,2014,23(10):1293-303.), cultivated to 3-5 generations for later use. After recovery and passage, the cells were digested with 0.25% trypsin, then inoculated in a 12-well cell culture plate, and cultured overnight with DMEM cell basal medium containing 10% fetal bovine serum. After preparing alpinine (AL) with different concentrations (10, 20, 40 μ M) with osteogenic induction medium (recipe is the same as in Example 1), add the MSCs derived from human beings cultured in 12-well plat...

Embodiment 3

[0034] Example 3 Alpinia can dose-dependently up-regulate the expression level of MSCs osteogenic differentiation index protein

[0035] MSCs were treated according to the administration method in Example 2. After 7 days and 14 days of osteogenic induction, the protein samples after cell lysis were collected, and the indicator proteins Runx2 and OCN in the process of MSCs osteogenic differentiation were detected by Western blotting. , OPN protein expression level (specific detection method reference: Li J, Wang P, Xie Z, et al. TRAF4 positively regulates the osteogenic differentiation of mesenchymalstem cells by acting as an E3ubiquitin ligase to degrade Smurf2[J]. Cell Deathand Differentiation, 2019 ,26(12); Literature 2: Wang Q, Li Y, Zhang Y, et al. LncRNA MEG3 inhibited osteogenic differentiation of bone marrow mesenchymal stem cells from postmenopausal osteoporosis by targeting miR-133a-3p[J].Biomedicine&pharmacotherapy=Biomedecine&pharmaco17 :1178.).

[0036] figure 2...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of medicines, particularly relates to application of alpinetin in preparation of medicines for preventing and treating osteoporosis, and provides new application of the alpinetin, namely application of the alpinetin in prevention and treatment of osteoporosis. The alpinia japonica can activate PKA/mTOR autophagy signals so as to up-regulate the expression levels of Runx2, OCN and OPN proteins in the osteogenic differentiation process of mesenchymal stem cells (MSCs), and finally enhance the osteogenic differentiation of the MSCs, so that the osteoporosis is effectively relieved, and the alpinia japonica can be applied to the development of medicines for efficiently preventing and treating the osteoporosis. The invention not only provides a new application of the alpinetin, but also provides a new therapeutic drug and a new therapeutic approach for the treatment of osteoporosis.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the application of alpinol in the preparation of medicines for preventing and treating osteoporosis. Background technique [0002] Osteoporosis is a systemic and systemic traditional skeletal disease characterized by bone defect and bone loss. With the increasing aging of the global population, osteoporosis has become a worldwide problem. At present, the clinical treatment of osteoporosis mainly adopts the treatment of drugs such as estrogen, calcitonin, and parathyroid hormone. However, these drugs are prone to cause vasoconstriction, venous thromboembolism, loss of calcium ions in the body, and complications such as breast cancer, cervical cancer, and endometrial cancer, and are very expensive. Therefore, in-depth exploration of effective and less toxic drugs for the prevention and treatment of osteoporosis and the elucidation of its specific mechanism of action a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61K36/9062A61P19/10A61K131/00
CPCA61K31/352A61K36/9062A61P19/10
Inventor 沈慧勇吴燕峰曾琛莹旺姗王子明陈锋磊
Owner 中山大学附属第八医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap